{"protocolSection":{"identificationModule":{"nctId":"NCT01297491","orgStudyIdInfo":{"id":"CBKM120D2201"},"secondaryIdInfos":[{"id":"2010-024011-14","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Novartis","class":"INDUSTRY"},"briefTitle":"Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer","officialTitle":"An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway","acronym":"BASALT-1"},"statusModule":{"statusVerifiedDate":"2016-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-05"},"primaryCompletionDateStruct":{"date":"2014-10","type":"ACTUAL"},"completionDateStruct":{"date":"2014-10","type":"ACTUAL"},"studyFirstSubmitDate":"2011-02-11","studyFirstSubmitQcDate":"2011-02-15","studyFirstPostDateStruct":{"date":"2011-02-16","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-10-30","resultsFirstSubmitQcDate":"2015-12-31","resultsFirstPostDateStruct":{"date":"2016-02-02","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-03-10","lastUpdatePostDateStruct":{"date":"2016-03-11","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novartis Pharmaceuticals","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this two-stage phase II study is to assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. BKM120 will be investigated in two groups of NSCLC patients according to the histology of the cancer: squamous and non-squamous."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["NSCLC","PI3K"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":63,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Squamous BKM120 100mg qd","type":"EXPERIMENTAL","description":"Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease.","interventionNames":["Drug: BKM120"]},{"label":"Non-Squamous BKM120 100mg qd","type":"EXPERIMENTAL","description":"Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease.","interventionNames":["Drug: BKM120"]}],"interventions":[{"type":"DRUG","name":"BKM120","description":"Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.","armGroupLabels":["Non-Squamous BKM120 100mg qd","Squamous BKM120 100mg qd"],"otherNames":["Buparlisib"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival (PFS) Rate as Per Investigator Local Review Measured Using RECIST 1.1 of Patients at Week 12","description":"PFS rate was defined as the percentage of participants who were progression free at 12 weeks. Participants were considered as a \"success\" for PFS rate evaluated at 12 weeks if they presented an overall response at their 2nd post-baseline tumor assessment.The enrollment into the study in either histology group would stop for futility if a PFS rate \\<50% at 12 weeks was observed.\n\nNo statistical analysis was planned for this primary outcome. The results of the primary objective was based on the data from the interim analysis that took place at the cut off dates: 10-Apr-2013 for non-squamous and 08-Jan-2014 for squamous group.","timeFrame":"Week 12"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS) Using Kaplan-Meier Estimates","description":"OS was defined as the time from start of study drug (Stage 1) until death from any cause. If a patient was not known to have died, survival was censored at the date of last contact.","timeFrame":"Every 8 weeks up to 24 months"},{"measure":"Overall Response Rate (ORR) Based on Investigator Assessment","description":"ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR). Complete response was defined as disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm. Partial response was defined as at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Analyses of response rates were performed based on investigators' assessments (as per RECIST 1.1 criteria). ORR included all patients with and without measurable disease at baseline.","timeFrame":"Every 6 weeks up to 24 months"},{"measure":"Disease Control Rate (DCR)","description":"DCR defined as the percentage of participants with best overall response of CR or PR or stable disease (SD). Complete response was defined as disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm. Partial response was defined as at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.\n\nAnalyses of response rates were performed based on investigators' assessments (as per RECIST 1.1 criteria). DCR included all participants with and without measurable disease at baseline.","timeFrame":"Every 6 weeks up tp 24 months"},{"measure":"Time to Response (TTR)","description":"TTR for a participant was defined as the time from the first treatment date to the date of first documented confirmed CR or PR evaluation. The date of event was defined as the date of response that was first determined and not using the date the response was confirmed.","timeFrame":"Every 6 weeks up to 24 months"},{"measure":"Duration of Response (DoR)","description":"DoR was defined as the elapsed time between the date of first documented CR or PR response (not the date of confirmed response) and the following date of event defined as the first documented progression or death due to underlying cancer.","timeFrame":"Every 6 weeks up to 24 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed NSCLC with activated PI3K pathway\n* Progressive disease after prior systemic antineoplastic treatment(s) for advanced NSCLC\n* Archival or fresh tumor biopsy must be available for profiling\n* Measurable and/or non-measurable disease as per RECIST 1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Adequate organ function as assessed by laboratory tests\n\nExclusion Criteria:\n\n* Patient has received previous treatment with PI3K inhibitors\n* Patient with squamous NSCLC has received more than one line of chemotherapy treatment for metastatic disease; patient with non-squamous NSCLC has received more than two lines of systemic antineoplastic treatment for metastatic disease\n* Uncontrolled or symptomatic CNS metastases\n* Concurrent use of any other approved or investigational antineoplastic agent\n* Radiotherapy ≤ 28 days prior to starting study drug\n* Major surgery within 28 days prior to starting study drug\n* History of clinically significant cardiac dysfunction, mood disorders, or poorly controlled diabetes mellitus\n* Current treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes\n* Impairment of gastrointestinal (GI) function\n* Chronic treatment with steroids or another immunosuppressive agent.\n* Concurrent severe and/or uncontrolled medical condition\n* Currently receiving Warfarin or another coumarin derivative\n* Known history of HIV infection\n* Sensory neuropathy with functional impairment (CTC grade 2 neuropathy, regardless of causality)\n* Pregnancy, lactation, or breastfeeding\n* Woman of child-bearing potential\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Novartis Pharmaceuticals","affiliation":"Novartis Pharmaceuticals","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Ironwood Cancer and Research Centers SC","city":"Chandler","state":"Arizona","zip":"85224","country":"United States","geoPoint":{"lat":33.30616,"lon":-111.84125}},{"facility":"Arizona Oncology Associates Tucson (Rudasill & La Cholla)","city":"Phoenix","state":"Arizona","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Mayo Clinic - Arizona Mayo Scottsdale AZ","city":"Scottsdale","state":"Arizona","zip":"85259","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"Highlands Oncology Group Dept of Highlands Oncology Grp","city":"Fayetteville","state":"Arkansas","zip":"72753","country":"United States","geoPoint":{"lat":36.06258,"lon":-94.15743}},{"facility":"Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr.","city":"Los Angeles","state":"California","zip":"90048","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"University of California at San Diego, Moores Cancer Ctr SC","city":"San Diego","state":"California","zip":"92103","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"University of Colorado Univ CO","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer","city":"Greenwood Village","state":"Colorado","zip":"80218","country":"United States","geoPoint":{"lat":39.61721,"lon":-104.95081}},{"facility":"H. Lee Moffitt Cancer Center & Research Institute H Lee Moffitt","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Emory University School of Medicine/Winship Cancer Institute Emory 2","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Rush University Medical Center SC","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"University of Chicago Medical Center Unvi Chi","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"University of Kansas Cancer Center Univ of KS","city":"Kansas City","state":"Kansas","zip":"66160","country":"United States","geoPoint":{"lat":39.11417,"lon":-94.62746}},{"facility":"Massachusetts General Hospital Mass General","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Fallon Clinic at Worcester Medical Center Fallon Clinic Worcester Med","city":"Worcester","state":"Massachusetts","zip":"01608","country":"United States","geoPoint":{"lat":42.26259,"lon":-71.80229}},{"facility":"Karmanos Cancer Institute Wayne St Karmanos","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Washington University School of Medicine Washington University (16)","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Hematology Oncology Associates of Northern New Jersey PA DeptofHem-OncofNorthern NJ (2)","city":"Morristown","state":"New Jersey","zip":"07962","country":"United States","geoPoint":{"lat":40.79677,"lon":-74.48154}},{"facility":"Overlook Hospital - Carol G Simon Cancer Center Carol G Simon","city":"Summit","state":"New Jersey","zip":"07901","country":"United States","geoPoint":{"lat":40.71562,"lon":-74.36468}},{"facility":"Roswell Park Cancer Institute Rosewell","city":"Buffalo","state":"New York","zip":"14263","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"Memorial Sloan Kettering Cancer Center Sloan Kettering","city":"New York","state":"New York","zip":"90033","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Duke University Medical Center Duke 2","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"MetroHealth Medical Center Dept.ofMetroHealthMedCtr.(2)","city":"Cleveland","state":"Ohio","zip":"44109-1998","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"University of Oklahoma Health Sciences Center Dept. of Oklahoma Univ. HSC","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Northwest Cancer Specialists Compass Oncology -BKM","city":"Portland","state":"Oregon","zip":"97210","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"University of Pittsburgh Medical Center SC-2","city":"Pittsburgh","state":"Pennsylvania","zip":"15213","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Medical University of South Carolina MUSC","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology","city":"Dallas","state":"Texas","zip":"75246","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Texas Oncology South Texas Oncology","city":"Dallas","state":"Texas","zip":"75251","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"U of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office","city":"Dallas","state":"Texas","zip":"75390-9151","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Virginia Oncology Associates VOA - Lake Wright (2)","city":"*see Various Departments*","state":"Virginia","zip":"23502","country":"United States"},{"facility":"University of Wisconsin Univ WIsc 2","city":"Madison","state":"Wisconsin","zip":"53792","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}},{"facility":"Novartis Investigative Site","city":"Buenos Aires","state":"Buenos Aires","zip":"C1050AAK","country":"Argentina"},{"facility":"Novartis Investigative Site","city":"Córdoba","state":"Córdoba Province","zip":"X5002AOQ","country":"Argentina","geoPoint":{"lat":-31.40648,"lon":-64.18853}},{"facility":"Novartis Investigative Site","city":"Rio Negro","state":"Viedma","zip":"8500","country":"Argentina"},{"facility":"Novartis Investigative Site","city":"Brussels","zip":"1090","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Novartis Investigative Site","city":"Charleroi","zip":"6000","country":"Belgium","geoPoint":{"lat":50.41136,"lon":4.44448}},{"facility":"Novartis Investigative Site","city":"Genk","zip":"3600","country":"Belgium","geoPoint":{"lat":50.965,"lon":5.50082}},{"facility":"Novartis Investigative Site","city":"Leuven","zip":"3000","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"Novartis Investigative Site","city":"Libramont","zip":"6800","country":"Belgium","geoPoint":{"lat":49.91741,"lon":5.37318}},{"facility":"Novartis Investigative Site","city":"Salvador","state":"Estado de Bahia","zip":"41253-190","country":"Brazil","geoPoint":{"lat":-12.97563,"lon":-38.49096}},{"facility":"Novartis Investigative Site","city":"Rio de Janeiro","state":"Rio de Janeiro","zip":"20230-130","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"Novartis Investigative Site","city":"Florianópolis","state":"Santa Catarina","zip":"88034-000","country":"Brazil","geoPoint":{"lat":-27.59667,"lon":-48.54917}},{"facility":"Novartis Investigative Site","city":"Barretos","state":"São Paulo","zip":"14784-400","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"Novartis Investigative Site","city":"São Paulo","state":"São Paulo","zip":"01246-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Novartis Investigative Site","city":"Vancouver","state":"British Columbia","zip":"V5Z 4E6","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Novartis Investigative Site","city":"Toronto","state":"Ontario","zip":"M5G 1Z5","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Novartis Investigative Site","city":"Montreal","state":"Quebec","zip":"H2X 3J4","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Novartis Investigative Site","city":"Caen","zip":"14021","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"Novartis Investigative Site","city":"Créteil","zip":"94000","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"facility":"Novartis Investigative Site","city":"Marseille","zip":"13915","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Novartis Investigative Site","city":"Rennes","zip":"F-35043","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"Novartis Investigative Site","city":"Villejuif","zip":"94805","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"facility":"Novartis Investigative Site","city":"Berlin","zip":"13125","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Novartis Investigative Site","city":"Cologne","zip":"51109","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Novartis Investigative Site","city":"Essen","zip":"45147","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Novartis Investigative Site","city":"Gauting","zip":"82131","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"Novartis Investigative Site","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Novartis Investigative Site","city":"Heidelberg","zip":"69120","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Novartis Investigative Site","city":"Nuremberg","zip":"90419","country":"Germany","geoPoint":{"lat":49.45421,"lon":11.07752}},{"facility":"Novartis Investigative Site","city":"Oldenburg","zip":"26121","country":"Germany","geoPoint":{"lat":53.14118,"lon":8.21467}},{"facility":"Novartis Investigative Site","city":"Recklinghausen","zip":"45657","country":"Germany","geoPoint":{"lat":51.61379,"lon":7.19738}},{"facility":"Novartis Investigative Site","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Novartis Investigative Site","city":"Budapest","zip":"1121","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Novartis Investigative Site","city":"Budapest","zip":"1125","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Novartis Investigative Site","city":"Deszk","zip":"6772","country":"Hungary","geoPoint":{"lat":46.21802,"lon":20.24322}},{"facility":"Novartis Investigative Site","city":"Mátraháza","zip":"3233","country":"Hungary","geoPoint":{"lat":47.87124,"lon":19.97981}},{"facility":"Novartis Investigative Site","city":"Szolnok","zip":"H-5000","country":"Hungary","geoPoint":{"lat":47.18066,"lon":20.19835}},{"facility":"Novartis Investigative Site","city":"Avellino","state":"AV","zip":"83100","country":"Italy","geoPoint":{"lat":40.91494,"lon":14.79103}},{"facility":"Novartis Investigative Site","city":"Genova","state":"GE","zip":"16132","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"Novartis Investigative Site","city":"Milan","state":"MI","zip":"20133","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Novartis Investigative Site","city":"Milan","state":"MI","zip":"20141","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Novartis Investigative Site","city":"Parma","state":"PR","zip":"43100","country":"Italy","geoPoint":{"lat":44.79935,"lon":10.32618}},{"facility":"Novartis Investigative Site","city":"Udine","state":"UD","zip":"33100","country":"Italy","geoPoint":{"lat":46.0693,"lon":13.23715}},{"facility":"Novartis Investigative Site","city":"Kurashiki","state":"Okayama-ken","zip":"710-8602","country":"Japan","geoPoint":{"lat":34.58333,"lon":133.76667}},{"facility":"Novartis Investigative Site","city":"Koto","state":"Tokyo","zip":"135-8550","country":"Japan"},{"facility":"Novartis Investigative Site","city":"Maastricht","zip":"6229 HX","country":"Netherlands","geoPoint":{"lat":50.84833,"lon":5.68889}},{"facility":"Novartis Investigative Site","city":"Singapore","state":"Singapore","zip":"169610","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Novartis Investigative Site","city":"Sabadell","state":"Barcelona","zip":"08208","country":"Spain","geoPoint":{"lat":41.54329,"lon":2.10942}},{"facility":"Novartis Investigative Site","city":"Barcelona","state":"Catalonia","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Novartis Investigative Site","city":"Mataró","state":"Catalonia","zip":"08301","country":"Spain","geoPoint":{"lat":41.54211,"lon":2.4445}},{"facility":"Novartis Investigative Site","city":"Alicante","state":"Valencia","zip":"03010","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Novartis Investigative Site","city":"Tainan","state":"Taiwan ROC","zip":"704","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"Novartis Investigative Site","city":"Taipei","state":"Taiwan ROC","zip":"100","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Novartis Investigative Site","city":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Novartis Investigative Site","city":"Chiang Mai","zip":"50200","country":"Thailand","geoPoint":{"lat":18.79038,"lon":98.98468}},{"facility":"Novartis Investigative Site","city":"Izmir","state":"Turkey","zip":"35040","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"facility":"Novartis Investigative Site","city":"Altunizade","zip":"34662","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01779,"lon":29.04794}},{"facility":"Novartis Investigative Site","city":"Northwood","state":"Middlesex","zip":"HA6 2RN","country":"United Kingdom","geoPoint":{"lat":51.61162,"lon":-0.42454}},{"facility":"Novartis Investigative Site","city":"Leicester","zip":"LE1 5WW","country":"United Kingdom","geoPoint":{"lat":52.6386,"lon":-1.13169}},{"facility":"Novartis Investigative Site","city":"London","zip":"SE1 9RT","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Novartis Investigative Site","city":"Manchester","zip":"M20 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}}]},"referencesModule":{"references":[{"pmid":"26098748","type":"RESULT","citation":"Vansteenkiste JF, Canon JL, De Braud F, Grossi F, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli C, Dy GK, Thongprasert S, Reck M, Aimone P, Vidam GA, Roussou P, Wang YA, Di Tomaso E, Soria JC. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study. J Thorac Oncol. 2015 Sep;10(9):1319-1327. doi: 10.1097/JTO.0000000000000607."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Squamous BKM120 100mg qd","description":"Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease."},{"id":"FG001","title":"Non-Squamous BKM120 100mg qd","description":"Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"33"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"33"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Progressive disease","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"20"}]},{"type":"Patient/Guardian decision","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Analysis set Stage 1 includes all patients who were enrolled during Stage 1 after meeting eligibility criteria and who have received at least one dose of study drug.","groups":[{"id":"BG000","title":"Squamous BKM120 100mg qd","description":"Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease."},{"id":"BG001","title":"Non-Squamous BKM120 100mg qd","description":"Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"63"}]}],"measures":[{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"< 65 years","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"31"}]}]},{"title":">= 65 years","categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"32"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"23"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"40"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS) Rate as Per Investigator Local Review Measured Using RECIST 1.1 of Patients at Week 12","description":"PFS rate was defined as the percentage of participants who were progression free at 12 weeks. Participants were considered as a \"success\" for PFS rate evaluated at 12 weeks if they presented an overall response at their 2nd post-baseline tumor assessment.The enrollment into the study in either histology group would stop for futility if a PFS rate \\<50% at 12 weeks was observed.\n\nNo statistical analysis was planned for this primary outcome. The results of the primary objective was based on the data from the interim analysis that took place at the cut off dates: 10-Apr-2013 for non-squamous and 08-Jan-2014 for squamous group.","populationDescription":"Analysis set Stage 1 includes all patients who were enrolled during Stage 1 after meeting eligibility criteria and who have received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Squamous BKM120 100mg qd","description":"Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease."},{"id":"OG001","title":"Non-Squamous BKM120 100mg qd","description":"Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","lowerLimit":"9.9","upperLimit":"42.3"},{"groupId":"OG001","value":"20.0","lowerLimit":"7.7","upperLimit":"38.6"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) Using Kaplan-Meier Estimates","description":"OS was defined as the time from start of study drug (Stage 1) until death from any cause. If a patient was not known to have died, survival was censored at the date of last contact.","populationDescription":"Analysis set Stage 1 includes all patients who were enrolled during Stage 1 after meeting eligibility criteria and who have received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Every 8 weeks up to 24 months","groups":[{"id":"OG000","title":"Squamous BKM120 100mg qd","description":"Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease."},{"id":"OG001","title":"Non-Squamous BKM120 100mg qd","description":"Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.98","lowerLimit":"5.95","upperLimit":"10.09"},{"groupId":"OG001","value":"7.20","lowerLimit":"4.01","upperLimit":"9.92"}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) Based on Investigator Assessment","description":"ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR). Complete response was defined as disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm. Partial response was defined as at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Analyses of response rates were performed based on investigators' assessments (as per RECIST 1.1 criteria). ORR included all patients with and without measurable disease at baseline.","populationDescription":"Analysis set Stage 1 includes all patients who were enrolled during Stage 1 after meeting eligibility criteria and who have received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Every 6 weeks up to 24 months","groups":[{"id":"OG000","title":"Squamous BKM120 100mg qd","description":"Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease."},{"id":"OG001","title":"Non-Squamous BKM120 100mg qd","description":"Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3"},{"groupId":"OG001","value":"3.0"}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR)","description":"DCR defined as the percentage of participants with best overall response of CR or PR or stable disease (SD). Complete response was defined as disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm. Partial response was defined as at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.\n\nAnalyses of response rates were performed based on investigators' assessments (as per RECIST 1.1 criteria). DCR included all participants with and without measurable disease at baseline.","populationDescription":"Analysis set Stage 1 includes all patients who were enrolled during Stage 1 after meeting eligibility criteria and who have received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Every 6 weeks up tp 24 months","groups":[{"id":"OG000","title":"Squamous BKM120 100mg qd","description":"Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease."},{"id":"OG001","title":"Non-Squamous BKM120 100mg qd","description":"Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7"},{"groupId":"OG001","value":"45.5"}]}]}]},{"type":"SECONDARY","title":"Time to Response (TTR)","description":"TTR for a participant was defined as the time from the first treatment date to the date of first documented confirmed CR or PR evaluation. The date of event was defined as the date of response that was first determined and not using the date the response was confirmed.","populationDescription":"Analysis set Stage 1 includes all patients who were enrolled during Stage 1 after meeting eligibility criteria and who have received at least 1 dose of study drug. 1 partial response was observed as best overall response (BOR) for 1 patient in the squamous group. Also,1 patient experienced partial response as BOR in the non-squamous group.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Days","timeFrame":"Every 6 weeks up to 24 months","groups":[{"id":"OG000","title":"Squamous BKM120 100mg qd","description":"Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease."},{"id":"OG001","title":"Non-Squamous BKM120 100mg qd","description":"Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"42"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"DoR was defined as the elapsed time between the date of first documented CR or PR response (not the date of confirmed response) and the following date of event defined as the first documented progression or death due to underlying cancer.","populationDescription":"Analysis set Stage 1 includes all patients who were enrolled during Stage 1 after meeting eligibility criteria and who have received at least 1 dose of study drug. 1 partial response was observed as best overall response (BOR) for 1 patient in the squamous group. Also,1 patient experienced partial response as BOR in the non-squamous group.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Days","timeFrame":"Every 6 weeks up to 24 months","groups":[{"id":"OG000","title":"Squamous BKM120 100mg qd","description":"Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease."},{"id":"OG001","title":"Non-Squamous BKM120 100mg qd","description":"Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"85"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Squamous BKM120 100 mg qd","description":"Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease.","seriousNumAffected":16,"seriousNumAtRisk":30,"otherNumAffected":29,"otherNumAtRisk":30},{"id":"EG001","title":"Non-Squamous BKM120 100 mg qd","description":"Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease.","seriousNumAffected":15,"seriousNumAtRisk":33,"otherNumAffected":32,"otherNumAtRisk":33}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Cardiogenic shock","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Blepharitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Local swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Hepatitis toxic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Escherichia sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Urinary tract infection pseudomonal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":33}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Acute pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":33}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":33}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Rash macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":33}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":30},{"groupId":"EG001","numAffected":11,"numAtRisk":33}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":30},{"groupId":"EG001","numAffected":9,"numAtRisk":33}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":4,"numAtRisk":33}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":30},{"groupId":"EG001","numAffected":5,"numAtRisk":33}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":30},{"groupId":"EG001","numAffected":12,"numAtRisk":33}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":30},{"groupId":"EG001","numAffected":6,"numAtRisk":33}]},{"term":"Hypothermia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":4,"numAtRisk":33}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":33}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":30},{"groupId":"EG001","numAffected":6,"numAtRisk":33}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":30},{"groupId":"EG001","numAffected":6,"numAtRisk":33}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Insulin c-peptide increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":33}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":30},{"groupId":"EG001","numAffected":12,"numAtRisk":33}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":30},{"groupId":"EG001","numAffected":11,"numAtRisk":33}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":33}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":33}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":30},{"groupId":"EG001","numAffected":4,"numAtRisk":33}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Myoclonus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":8,"numAtRisk":33}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":33}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":30},{"groupId":"EG001","numAffected":11,"numAtRisk":33}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Mood altered","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":4,"numAtRisk":33}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":30},{"groupId":"EG001","numAffected":6,"numAtRisk":33}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":30},{"groupId":"EG001","numAffected":7,"numAtRisk":33}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":33}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":30},{"groupId":"EG001","numAffected":5,"numAtRisk":33}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":33}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":30},{"groupId":"EG001","numAffected":4,"numAtRisk":33}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":30},{"groupId":"EG001","numAffected":6,"numAtRisk":33}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":33}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety."},"pointOfContact":{"title":"Study Director","organization":"Novartis Pharmaceuticals","email":"trialandresults.registries@novartis.com","phone":"862-778-8300"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["China","South Korea"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C571178","term":"NVP-BKM120"}]}},"hasResults":true}